Clinical and metabolic characterization of patients with a diagnosis of urolithiasis in a four-level clinic in the city of Barranquilla
PDF (Español (España))
XML (Español (España))

Keywords

Urolithiasis
hypercalciuria
uric acid
epidemiology
Colombia

How to Cite

1.
Licona Vera ER, Pérez Padilla RV, Torrens Soto JE, Abuabara Franco E, Caballero Rodriguez LR, Cerda Salcedo JE, Ramos Clason EC, Caballero Rodriguez CJ, Hoyos Montaño IP, Morales Jurado LF, Pabón Vera FA, Serna Vera JC. Clinical and metabolic characterization of patients with a diagnosis of urolithiasis in a four-level clinic in the city of Barranquilla: Caracterización clínica y metabólica depacientes con diagnóstico de urolitiasisatendidos en una clínica de cuarto nivel deBarranquilla, Colombia. Rev. Colomb. Nefrol. [Internet]. 2020 Dec. 22 [cited 2022 Sep. 24];8(1):e472. Available from: https://revistanefrologia.org/index.php/rcn/article/view/472

Abstract

Introduction:
Urolithiasis is a disease with high frequency and our environment is no exception. Previous studies have been published in Colombia, however, these do not compare the sociodemographic and clinical characteristics of patients with comorbidities and predisposing factors for lithiasis such as they are hyperuricemia, high blood pressure, obesity, and chronic kidney disease (CKD).

Objectives:

To characterize clinically and metabolically the patients diagnosed with urolithiasis in a fourth-level clinic in the city of Barranquilla in 2019.

 

Materials and methods:
Observational, descriptive, cross-sectional study. In 49 patients, based on the study of clinical records.

Results:
The median age was 58 years, the male sex in 53.1 %. The median body mass index was 26.4 Kg/m2. High blood pressure was identified in 69.4 %, chronic kidney disease (CKD) in 36.7 %, recurrent urinary tract infection in 24.5 %. Hyperuricemia in 44.9 %, hypercalcemia in 16.3 % and hyperphosphatemia in 12.2 %. The crystal types were oxalate in 20.4 %, urate in 12.2 %, mixture of the previous ones in 4.1 % and in the same proportion phosphate. Hypercalciuria and hyperoxaluria in 38.8 %, hyperuricosuria and hypocalciuria in 18.4 %, while hyperphosphaturia or hypophosphaturia in 4.1 %. Hyperuricemia was associated with age (p = 0.028), CKD (p = 0.026), antihypertensive drugs (p = 0.022), the position of the stone in the renal calyx (p = 0.012), hyperparathyroidism (p = 0.007), creatinine clearance (p = 0.046) and hypercalciuria (p = 0.049). BMI ? 30 was associated with stage 5 CKD (p = 0.025), dialysis (p = 0.025), and hyperoxaluria (p = 0.021).

Conclusions:
A significant frequency of CKD, hyperuricemia, obesity and hypertension was evidenced in patients with urolithiasis.

https://doi.org/10.22265/acnef.8.1.472
PDF (Español (España))
XML (Español (España))

References

Garcia-Nieto VM, Luis-Yanes MI. Litiasis renal. En: Lorenzo V, López Gómez JM (Eds).Nefrología al día. Litiasis Renal. Barcelona: Grupo Editorial Nefrología; 2019. p. 133-47.

Dos Santos FM, Peres AK, Mandotti MR, Peres LAB. Metabolic investigation in patients with nephrolithiasis. Einstein (Sao Paulo) 2017;15:452-6. https://doi.org/10.1590/s1679-45082017ao4029

Khan SR, Pearle MS, Robertson WG, Gambaro G, Canales BK, Doizi S, et al. Kidney stones. Nat Rev Dis Prim 2016;2:1-23. https://doi.org/10.1038/nrdp.2016.8

Ziemba JB, Matlaga BR. Epidemiology and economics of nephrolithiasis. Investig Clin Urol 2017;58:299-306. https://doi.org/10.4111/icu.2017.58.5.299

Aponte V HA, Blanco R LA, Hernández S FL, Larios G. CA, Romero W. G, Salazar T. GA, et al. Guías de estudio metabólico de la litiasis. Basadas en la evidencia. Rev Urol Colomb / Colomb Urol J 2006;XV:117-21

Pfau A, Knauf F. Update on Nephrolithiasis: Core Curriculum 2016. Am J Kidney Dis 2016;68:973-85. https://doi.org/10.1053/j.ajkd.2016.05.016

Tang X, Lieske JC. Acute and chronic kidney injury in nephrolithiasis. Curr Opin NephrolHypertens. 2014;23(4):385-90. https://dx.doi.org/10.1097/01.mnh.0000447017.28852.52

Ordoñez J, De Reina G. Diagnóstico y manejo clínico del paciente con Urolitiasis. Acta Medica Colomb 1978;3:111-24.

Fink HA, Wilt TJ, Eidman KE, Garimella PS, MacDonald R, Rutks IR, et al. Medical management to prevent recurrent nephrolithiasis in adults: A systematic review for an American College of Physicians Clinical Guideline. Ann Intern Med 2013;158:535-43. https://doi.org/10.7326/0003-4819-158-7-201304020-00005

Spivacow FR, Del Valle EE, Lores E, Rey PG. Kidney stones: Composition, frequency and relation to metabolic diagnosis. Medicina (B Aires) 2016;76:343-8.

Rodríguez CE. Análisis metabólico de los pacientes con litiasis renal. Papel de la hipocitraturia en la génesis de los cálculos de oxalato de calcio. Rev La Fac Med 1996;44:70-4.

Gordiano EA, Tondin LM, Miranda RC de, Baptista DR, Carvalho M. Evaluation of food intake and excretion of metabolites in nephrolithiasis. J Bras Nefrol 2014;36:437-45. https://doi.org/10.5935/0101-2800.20140063

Cuenta de alto costo. Situación de la enfermedad renal crónica, la hipertensión arterial y la diabetes mellitus en Colombia - 2018 2018:1-65.

Peres LAB, de Almeida LP, Bolson LB, Brites M de F, David JM, Tazima L. Investigation of nephrolithiasis in the West of Paraná. J Bras Nefrol 2011;33:160-5. https://doi.org/10.1590/S0101-28002011000200007

Arrabal M, Rodríguez Fernández A, Arrabal Polo MÁ, Ruíz Garcia MJ, Zuluaga Gomez A. Estudio de factores físico-químicos en pacientes con litiasis renal. Arch Españoles Urol 2006;59:583-94. https://doi.org/10.4321/S0004-06142006000600004

González G. Litiasis renal: estudio y manejo endocrinológico. Rev Médica Clínica LasCondes. 2013;24(5):798-803. https://dx.doi.org/10.1016/S0716-8640(13)70226-8.

Cano-García M del C, Ochoa-Hortal MÁ. Value of urinary metabolic study in patients with recurrent renal stones. Study in or a Health Area. Actual Medica 2014;99:136-9. https://doi.org/10.15568/am.2014.793.or04

Fink HA, Wilt T, Eidman K. Recurrent Nephrolithiasis in Adults?: Comparative Effectiveness of Preventive. Agency Healthc Res Qual 2013.

García-Perdomo HA, Solarte PB, España PP. Fisiopatología asociada a la formación de cálculos en la vía urinaria. Urol Colomb 2016;25:109-17. https://doi.org/10.1016/j.uroco.2015.12.012

Jungers P, Joly D, Barbey F, Choukroun G, Daudon M. ESRD caused by nephrolithiasis: Prevalence, mechanisms, and prevention. Am J Kidney Dis 2004;44:799-805. https://doi.org/10.1016/S0272-6386(04)01131-X

Amato M, Lusini ML, Nelli F. Epidemiology of nephrolithiasis today. Urol Int 2004;72:1-5. https://doi.org/10.1159/000076582

Cicerello E, Mangano M, Cova GD, Merlo F, Maccatrozzo L. Metabolic evaluation in patients with infected nephrolithiasis: Is it necessary? Arch Ital Di Urol e Androl 2016;88:208-11. https://doi.org/10.4081/aiua.2016.3.208

Sakhaee K. Unraveling the mechanisms of obesity-induced hyperoxaluria. Kidney Int 2018;93:1038-40. https://doi.org/10.1016/j.kint.2018.01.012

Hsu C, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body Mass Index and Risk for End-Stage Renal Disease. Ann Intern Med 2006;144:21. https://doi.org/10.7326/0003-4819-144-1-200601030-00006

Sohgaura A, Bigoniya P. A Review on Epidemiology and Etiology of Renal Stone. Am JDrug Discov Dev. 2017;7:54-62. https://dx.doi.org/10.3923/ajdd.2017.54.62.

Kim YJ, Kim CH, Sung EJ, Kim SR, Shin HC, Jung WJ. Association of nephrolithiasis with metabolic syndrome and its components. Metabolism 2013;62:808-13. https://doi.org/10.1016/j.metabol.2012.12.010

Masterson JH, Woo JR, Chang DC, Chi T, L'Esperance JO, Stoller ML, et al. Dyslipidemia is associated with an increased risk of nephrolithiasis. Urolithiasis 2015;43:49-53. https://doi.org/10.1007/s00240-014-0719-3

Parmar MS. Kidney stones. BMJ 2004;328:1420-4. https://doi.org/10.1136/bmj.328.7453.1420-4

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2020 Revista Colombiana de Nefrología

Dimensions


PlumX


Downloads

Download data is not yet available.